ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 1,709,714 shares, a growth of 0.0% from the November 15th total of 1,709,519 shares. Currently, 4.9% of the shares of the company are sold short. Based on an average daily volume of 1,305,592 shares, the short-interest ratio is currently 1.3 days.

Shares of ImmunoCellular Therapeutics (NYSEAMERICAN IMUC) opened at $0.23 on Wednesday. ImmunoCellular Therapeutics has a 12 month low of $0.03 and a 12 month high of $4.27.

Separately, Maxim Group restated a “hold” rating on shares of ImmunoCellular Therapeutics in a research note on Thursday, August 24th.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with's FREE daily email newsletter.